{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:20:52Z","timestamp":1783639252342,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-023-02437-w","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T09:06:00Z","timestamp":1677834360000},"page":"1818-1829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association Between Myasthenia Gravis\u2013Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7315-3230","authenticated-orcid":false,"given":"Sarah","family":"Dewilde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Iannazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-6949","authenticated-orcid":false,"given":"Mathieu F.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"4","key":"2437_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","volume":"20","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Xin H, Ltalien GJ, Harris LA, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis. 2019;20(4):173\u201381.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"2437_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2437_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"key":"2437_CR4","unstructured":"European Medicines Agency. EU\/3\/18\/1992: orphan designation for the treatment of myasthenia gravis. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3181992. Accessed 31 Jan 2023."},{"issue":"5","key":"2437_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259\u201368.","journal-title":"Nat Rev Neurol"},{"key":"2437_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11:553626.","journal-title":"Front Neurol"},{"issue":"4","key":"2437_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mus.1034","volume":"24","author":"RH Paul","year":"2001","unstructured":"Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve. 2001;24(4):512\u20136.","journal-title":"Muscle Nerve"},{"key":"2437_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G, et al. The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci. 2022;437:120268.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2437_CR9","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445.","journal-title":"BMJ Open"},{"issue":"7","key":"2437_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"key":"2437_CR11","doi-asserted-by":"crossref","unstructured":"EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2437_CR12","unstructured":"EuroQol Research Foundation. EQ-5D User Guides. Rotterdam, Netherlands; 2022."},{"key":"2437_CR13","unstructured":"EuroQol Research Foundation. EQ-5D. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed 30 Jan 2023."},{"issue":"3","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/ene.13836","volume":"26","author":"C Barnett","year":"2019","unstructured":"Barnett C, Bril V, Bayoumi AM. EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis. Eur J Neurol. 2019;26(3):452\u20139.","journal-title":"Eur J Neurol"},{"key":"2437_CR15","unstructured":"National Institute for Health and Care Excellence. NICE Health Technology Evaluations: the manual. www.nice.org.uk\/process\/pmg36. Accessed 31 Jan 2022."},{"issue":"8","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245\u201357.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2437_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5\u201321.","journal-title":"Br Med Bull"},{"key":"2437_CR18","unstructured":"Institute for Clinical and Economic Review. Myasthenia gravis: an assessment of efgartigimod and eculizumab. Final Report. October 2021. https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf. Accessed June 2, 2022."},{"key":"2437_CR19","doi-asserted-by":"crossref","unstructured":"Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8).","DOI":"10.3390\/jcm11082189"},{"issue":"3","key":"2437_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JND-200484","volume":"7","author":"RHP de Meel","year":"2020","unstructured":"de Meel RHP, Barnett C, Bril V, Tannemaat MR, Verschuuren J. Myasthenia gravis impairment index: sensitivity for change in generalized muscle weakness. J Neuromuscul Dis. 2020;7(3):297\u2013300.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"2437_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-8-54","volume":"8","author":"KA Goldsmith","year":"2010","unstructured":"Goldsmith KA, Dyer MT, Buxton MJ, Sharples LD. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease. Health Qual Life Outcomes. 2010;8:54.","journal-title":"Health Qual Life Outcomes"},{"key":"2437_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","volume":"11","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H. Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol. 2020;11: 596382.","journal-title":"Front Neurol"},{"issue":"5","key":"2437_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"11","key":"2437_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"key":"2437_CR26","doi-asserted-by":"crossref","unstructured":"Devlin N, Roudijk B, Ludwig K, editors. Value sets for EQ-5D-5L: a compendium, comparative review & user guide. Dordrecht: Springer; 2022.","DOI":"10.1007\/978-3-030-89289-0"},{"key":"2437_CR27","doi-asserted-by":"crossref","unstructured":"Vu T, Meisel A, Mantegazza R, et al. Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase\u00a03 CHAMPION MG Study (P1\u20131.Virtual). Neurology. 2022;98(18 Suppl):791.","DOI":"10.1056\/EVIDoa2100066"},{"key":"2437_CR28","unstructured":"Argenx. Data on file. Summary of analyses conducted on the ADAPT(+) dataset on the association of MG-ADL and EQ-5D utility. June 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02437-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02437-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02437-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:41:52Z","timestamp":1680518512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02437-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02437-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}